CD44 and neoplasm: Al-Hajj et al. (2003) demonstrated that the EpCAM+, CD44+, CD24−, and lineage− fraction of BCSC had a >10-fold increase in the frequency of tumor-initiating cells, when compared to the EpCAM−, CD44+, CD24−, and lineage− BCSC fraction.